This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

AACR-NCI-EORTC Boston, MA, USA 26-30 October 2019

A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable metastatic colorectal cancer cohor

Johanna Bendell, Susanna V Ulahannan, Quincy Chu, Manish Patel, Ben George, Mabrouk Elgadi, Christine Duffy, Ralph Graeser, WenboTang, Michael Merger, Miaomiao Ge, Melissa Johnson

bendell_1381.2_crc_aacr-nci-eortc_2019_final_poster
supplementary_material_1381.2_poster_

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Supplemental Slides

Study 1381.2: Key eligibility criteria for cohorts open for recruitment Study 1381.2: Endpoints and assessments in Part 2

RELATED INFORMATION

LAG-3 inhibitor (BI 754111) + PD-1 inhibitor (BI 754091)

LAG-3 inhibitor (BI 754111) + PD-1 inhibitor (BI 754091)

LAG-3 inhibitor (BI 754111)

Learn more about BI’s LAG-3 inhibitor, currently being investigated in combination with a PD-1 inhibitor for the treatment of solid tumours

PD-1 inhibitor (BI 754091)

BI 754091 is a PD-1 inhibitor that binds to the PD-1 receptor, thereby blocking signalling downstream from PD-1 and allowing T cell-mediated tumour cell destruction
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY

links_to_3rd_party.jpg